IPM Take
This report turns cancer inequality into a delivery-performance issue. Europe can invest in advanced cancer innovation and still fail patients if diagnosis happens through emergency rooms, treatment starts too late or care remains fragmented. For IPM, this is exactly where access intelligence matters: the question is not only which country has innovation, but which system can move a patient through the pathway without losing time, quality or support.
Executive Summary
The 2026 European Cancer Inequalities Registry analytical report, Delivering High Value Cancer Care, was published by the OECD and European Commission. It provides cross-country analysis across the EU27, Norway and Iceland, focusing on timely access to care, evidence-based and efficient care, and people-centred approaches. The Registry highlights major pathway gaps: 1 in 3 lung cancers are detected via the emergency room, and 4 in 10 colorectal cancers remain untreated 30 days after diagnosis. It also notes that cancer incidence in the EU has risen by 30% since 2000 and that per-capita cancer health spending is projected to increase by 59% by 2050.
Why it matters
- Policymakers: Need to measure cancer systems by pathway performance, not only by strategy documents or innovation availability.
- Hospitals / providers: Should focus on delays, emergency diagnosis, treatment initiation and care coordination as core quality indicators.
- Patients / advocates: Can use the report to push for faster diagnosis, more consistent treatment access and better support beyond the hospital setting.
Previously, European cancer inequalities were often discussed through mortality gaps, screening coverage or access to medicines. This report pushes the debate further. It asks whether cancer systems are actually delivering value in practice.
What has changed is the focus on pathway performance. Delayed diagnosis, delayed treatment, hospital dependence, surgical outcomes and weak coordination become measurable signs of system readiness. For personalised oncology, that matters because precision testing and targeted therapies cannot compensate for late diagnosis or broken referral pathways.
The report also shifts the discussion from spending more to spending better. It frames high-value cancer care around timely, coordinated diagnosis and treatment; more efficient and evidence-based care; and support that reflects patients’ practical, psychological, social and financial needs.
The implication is direct: cancer policy now needs to measure not only whether innovation exists, but whether patients move through the system fast enough to benefit from it. If Europe wants personalised oncology to be equitable, it has to fix the basic pathway failures that decide who reaches precision care in time.
